博瑞医药(688166) - 2024 Q4 - 年度业绩

Financial Performance - In 2024, the company achieved total operating revenue of RMB 128,255.16 million, a year-on-year increase of 8.74% driven by product sales growth[6] - The net profit attributable to the parent company was RMB 19,628.50 million, a decrease of 3.05% compared to the previous year, primarily due to increased R&D expenses related to products like BGM0504 injection[6] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 18,620.97 million, showing a slight decrease of 0.06% year-on-year[6] - Basic earnings per share for the period were RMB 0.46, down 4.17% from RMB 0.48 in the previous year[4] - The weighted average return on net assets decreased by 0.74 percentage points to 8.10%[4] Assets and Equity - The company's total assets at the end of 2024 were RMB 516,636.75 million, reflecting a growth of 2.67% from the beginning of the period[6] - The equity attributable to the parent company increased to RMB 240,136.31 million, up 1.38% from the start of the year[6] Research and Development - The company continues to adhere to a "R&D-driven" strategy, which has led to increased investment in product development[6] Financial Reporting - The financial data presented is preliminary and unaudited, with final figures to be confirmed in the annual report[8] - Investors are advised to be aware of investment risks associated with the preliminary financial data[8]